GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the di…
$82.38-1.64%
报价 2026-11-06
市值
$37.25B
EV
$44.8B
PE (TTM)
21.3x
预期 PE (FY2026)
16.4x
52 周区间距高点 -6.6%
$59.49$88.16
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 4.90 → 5.52（1.1x） | 14.9 |
| FY+32028-12 | 1.2x | 4.90 → 6.13（1.3x） | 13.4 |
毛利率 43% · TTM 收入 $20613M · 基数 EPS 4.90（调整后）
电话会信号
辅助标签Q3 20262026-10-28
扩产AI 词频高积压订单词频高上调指引供不应求
指引 上调
信心 4
分析师 4
“We feel very good about the $500 million exiting 2028 for Vercado.”
原文引用（3）
- 扩产：We are investing in strengthening our supply chain and manufacturing capabilities
- 上调指引：we are raising several of our full year 2026 metrics
- 供不应求：this market right now today capacity is maxed out
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| GEHCGE HealthCare Technologies Inc. | $37.25B | -1.6% | +6.5% | 40.3% | 21.3x | 14.0x | 30.9x | |
| CAHCardinal Health, Inc. | $62.92B | +1.5% | +3.9% | 4.3% | 31.6x | 16.9x | 11.9x | |
| HUMHumana Inc. | $52.08B | +5.3% | +25.8% | 11.7% | 41.8x | 17.8x | 69.7x | |
| AAgilent Technologies, Inc. | $49.28B | +1.7% | +6.1% | 26% | 27.1x | 23.0x | 39.3x | |
| IQVIQVIA Holdings Inc. | $44.8B | +2.6% | +8.0% | 32.9% | 33.1x | 16.6x | 16.9x | |
| ONCBeOne Medicines Ltd. | $43.49B | +5.1% | – | 86.9% | 160.5x | 56.0x | – | |
| ALCAlcon Inc. | $36.23B | -2.1% | – | 54.8% | 37.0x | 21.0x | – | |
| MTDMettler-Toledo International Inc. | $34.51B | +2.6% | +6.0% | 57.5% | 29.1x | 22.2x | 40.6x | |
| RMDResMed Inc. | $33.1B | -1.7% | +7.6% | 61% | 22.5x | 15.9x | 18.6x | |
| 同行中位数 | – | – | +6.8% | 43.8% | 32.3x | 19.4x | 28.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.51B | $5.3B | $5.13B | $4.67B | $5.14B | $5.01B | $4.78B | $5.32B |
| Gross Margin | 40.3% | 41.2% | 38.5% | 54.3% | 38.7% | 39.7% | 42.1% | 42.8% |
| Operating Margin | 14.6% | 14% | 10% | 14.2% | 12.7% | 13.1% | 13.2% | 15.1% |
| Net Income | $614M | $573M | $389M | $184M | $446M | $486M | $564M | $720M |
| Diluted EPS | 1.36 | 1.24 | 0.85 | 0.38 | 0.98 | 1.06 | 1.23 | 1.57 |
| Operating Cash Flow | $907M | $-517M | $290M | $1.05B | $593M | $94M | $250M | $913M |